Search results for "Neoplasms"

showing 10 items of 7988 documents

Progestogens and risk of breast cancer: a link between bone and breast?

2015

This article reviews the data supporting the role of receptor activator of the nuclear factor kappa (RANK) and its ligand, RANKL, in progestogen-induced breast cancer. Both experimental and clinical studies have been included. The expression of both RANK and RANKL has been described in epithelial cells of both mice and humans. Experiments of gain and loss of function in mice have shown that RANK/RANKL mediate alveologenesis during pregnancy or the estrous cycle. Moreover, the participation of the RANK/RANKL has been detected in models of breast carcinogenesis associated with progestogens-like medroxyprogesterone acetate. Recent clinical studies have found that the expression of RANK is asso…

musculoskeletal diseases0301 basic medicineEndocrinology Diabetes and MetabolismOsteoclastsBone NeoplasmsBreast NeoplasmsMice03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerRisk FactorsmedicineAnimalsHumansMedroxyprogesterone acetateBreastReceptorProgesteroneLoss functionEstrous cyclePregnancyReceptor Activator of Nuclear Factor-kappa BbiologyActivator (genetics)business.industryRANK LigandObstetrics and Gynecologymedicine.disease030104 developmental biologyRANKL030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchFemaleProgestinsbusinessmedicine.drugGynecological Endocrinology
researchProduct

The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing s…

2016

SATB2 is commonly expressed in osteosarcomas. Although apparently being a valuable diagnostic marker for differentiating between small cell osteosarcoma (SCO) and other small round cell tumors of bone, for instance Ewing sarcoma family of tumors (ESFT), it has not been tested in a large series of ESFT and chondrosarcomas so far. We studied the immunohistochemical expression of SATB2 in 42 osteosarcomas, 31 chondrosarcomas, and 371 genetically confirmed ESFT. SATB2 positivity was detected in 90.4% of osteosarcomas, 87.5% of SCO, 91.3% of osteoblastic osteosarcomas, and in all chondroblastic and parosteal osteosarcomas. The osteoblastic and SCO subtypes expressed SATB2 more intensely than oth…

musculoskeletal diseases0301 basic medicinePathologymedicine.medical_specialtyCD99ChondrosarcomaBone NeoplasmsSarcoma EwingSensitivity and SpecificitySmall Cell OsteosarcomaPathology and Forensic MedicineDiagnosis Differential03 medical and health sciences0302 clinical medicineChondroblastic OsteosarcomaBiomarkers TumormedicineHumansRetrospective StudiesOsteosarcomabusiness.industryOsteoidMatrix Attachment Region Binding ProteinsCell Biologymusculoskeletal systemmedicine.diseaseImmunohistochemistry030104 developmental biology030220 oncology & carcinogenesisImmunohistochemistryOsteosarcomaSarcomaChondrosarcomabusinessTranscription FactorsPathology - Research and Practice
researchProduct

Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers

2021

BackgroundHypercalcemia is a common paraneoplastic syndrome which can occur in up to 10% of patients with advanced neoplasms. Paraneoplastic parathyroid hormone-related protein (PTHrP) represents the most frequent cause of this syndrome. In neuroendocrine neoplasms (NENs) paraneoplastic hypercalcemia is rare.Case SeriesThe present series includes all patients with NENs and paraneoplastic hypercalcemia from four Italian centres: (I) A 40-year-old man was hospitalized for repeated episodes of falls, hyposthenia and drowsiness. Severe hypercalcemia was found. Metastatic pancreatic G2 NEN and PTHrP-related hypercalcemia were diagnosed. The patient started therapy with somatostatin analogs (SSA)…

musculoskeletal diseasesAdultMalemedicine.medical_specialty125-dihydroxyvitamin Dbronchial carcinoidEndocrinology Diabetes and Metabolism1pancreatic NENCase ReportGastroenterologyDiseases of the endocrine glands. Clinical endocrinologyparaneoplastic hypercalcemia; parathyroid hormone-related protein; pancreatic nen; bronchial carcinoid; 125-dihydroxyvitamin dEndocrinologyparaneoplastic hypercalcemiaInternal medicinemedicineHumansVitamin DAgedEverolimusmedicine.diagnostic_testPerformance statusParathyroid hormone-related proteinbusiness.industryparathyroid hormone-related proteinMiddle AgedRC648-665PrognosisPancreatic NeoplasmsNeuroendocrine TumorsSomatostatinDenosumabPositron emission tomographyCalcitoninRadionuclide therapyHypercalcemiaFemalebusiness25-dihydroxyvitamin dhormones hormone substitutes and hormone antagonistsmedicine.drugFrontiers in Endocrinology
researchProduct

Parosteal osteosarcoma of the talus.

1995

A case of parosteal osteosarcoma in the very rare location of the talus is presented. The radiological, pathological, and clinical characteristics of parosteal osteosarcoma are described and the differential diagnosis discussed.

musculoskeletal diseasesAdultMalemedicine.medical_specialtyPathologyBone NeoplasmsParosteal osteosarcomaLower limbTalusDiagnosis DifferentialmedicineHumansRadiology Nuclear Medicine and imagingneoplasmsTomographybusiness.industrymusculoskeletal systemmedicine.diseaseOsteosarcoma JuxtacorticalMagnetic Resonance ImagingOsteosarcomaRadiologyDifferential diagnosisNeoplasm Recurrence LocalbusinessTomography X-Ray ComputedFollow-Up StudiesSkeletal radiology
researchProduct

Hyperplastic callus formation in osteogenesis imperfecta: CT and MRI findings.

1998

Hyperplastic callus formation is a noteworthy condition in patients with osteogenesis imperfecta because it often mimicks osteosarcoma on radiography. The findings of CT and MRI in hyperplastic callus formation have not been reported. In the presented case, MRI demonstrated contrast enhancement and edema of the surrounding soft tisssue, consistent with benign as well as malignant disease. Computed tomography showed a calcified rim of the lesion which may be a useful feature to rule out osteosarcoma in this condition.

musculoskeletal diseasesAdultmedicine.medical_specialtyRadiographyBone NeoplasmsLesionDiagnosis DifferentialEdemamedicineHyperplastic callus formationHumansRadiology Nuclear Medicine and imagingBony CallusNeuroradiologyOsteosarcomaHyperplasiamedicine.diagnostic_testTibiabusiness.industryMagnetic resonance imagingGeneral MedicineOsteogenesis Imperfectamedicine.diseaseMagnetic Resonance ImagingOsteogenesis imperfectaFibulaOsteosarcomaFemaleRadiologymedicine.symptombusinessTomography X-Ray ComputedEuropean radiology
researchProduct

Clonal heterogeneity of the growth and invasive response of a human breast carcinoma cell line to parathyroid hormone-related peptide fragments

1997

It has been previously reported that 8701-BC cells, derived from a primary carcinoma of the breast, constitutively express parathyroid hormone (PTH)-related peptide (PTHrP) and PTH/PTHrP receptor (PTH/PTHrP-R) genes, that N-terminal, mid-regional and C-terminal immunoreactive PTHrP can be found in cell conditioned medium and, furthermore, that exogenously added PTHrP (1-34), (67-86) and, to a minor extent, (107-139) are anti-mitogenic but promote Matrigel invasion by this cell line. It has also been reported that PTHrP gene expression is selectively switched on in those 8701-BC clonal lines endowed with a higher proliferation rate and invasive ability in vitro. Here we have first examined t…

musculoskeletal diseasesCancer Researchmedicine.medical_specialtyPopulationParathyroid hormoneBreast NeoplasmsBiologyInternal medicineGene expressionTumor Cells CulturedmedicineHumansNeoplasm Invasivenesseducationeducation.field_of_studyParathyroid hormone-related proteinCell growthParathyroid hormone receptorParathyroid Hormone-Related ProteinProteinsGeneral Medicinemusculoskeletal systemMolecular biologyPeptide FragmentsNeoplasm ProteinsEndocrinologyParathyroid HormoneCell cultureFemaleClone (B-cell biology)Cell Divisionhormones hormone substitutes and hormone antagonistsCarcinogenesis
researchProduct

Expression of 60-kD Heat Shock Protein Increases during Carcinogenesis in the Uterine Exocervix

2002

<i>Objectives:</i> The aim of the present study was to determine the presence and expression of the 60-kD heat shock protein (HSP60) in the dysplasia-carcinoma sequence in the uterine exocervix and to evaluate its diagnostic and prognostic significance. <i>Methods and Results:</i> We performed Western blot and immunohistochemical analyses on biopsies from 40 cases, consisting of 10 normal exocervical biopsies, 10 low-grade squamous intraepithelial lesions (L-SIL), 10 high-grade squamous intraepithelial lesions (H-SIL) and 10 cancerous exocervices (G2 grade). The immunohistochemical results were quantified by computer-assisted image analysis. Western blot analysis sho…

musculoskeletal diseasesKoilocytePathologymedicine.medical_specialtyChaperonin; High-grade squamous intraepithelial lesion; Koilocyte; Low-grade squamous intraepithelial lesion; Squamous cervical cancer; 2734; Clinical Biochemistry; Immunology and Allergy; Cell BiologyBlotting Western2734Clinical BiochemistryUterine Cervical NeoplasmsBiologyChaperoninPathology and Forensic MedicineWestern blotimmune system diseasesLow-grade squamous intraepithelial lesionhemic and lymphatic diseasesHeat shock proteinImage Processing Computer-AssistedmedicineCarcinomaHumansImmunology and AllergyMolecular Biologymedicine.diagnostic_testChaperonin 60Cell BiologyGeneral MedicinePrognosisUterine Cervical Dysplasiamedicine.diseaseImmunohistochemistryMolecular biologyfemale genital diseases and pregnancy complicationsKoilocyteEpitheliumBlotmedicine.anatomical_structureHigh-grade squamous intraepithelial lesionCarcinoma Squamous CellImmunohistochemistryFemalePrecancerous ConditionsSquamous cervical cancerImmunostainingPathobiology
researchProduct

Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an…

2020

Introduction Pharmacokinetic interaction of high-dose methotrexate (MTX) and other concomitantly administered renally secreted medicinal products may lead to insufficient methotrexate serum level decrease and significant MTX toxicity. Case report We report the case of an 18-year-old male patient treated with high-dose MTX for an osteosarcoma and with high-dose piperacillin-tazobactam at the same time. MTX serum levels were severely elevated 24 hours after the MTX infusion and did not decrease in accordance with the specific calcium folinate rescue protocol. The patient experienced renal failure accompanied by neurological symptoms, most consistent with MTX-related renal and CNS toxicity. Ma…

musculoskeletal diseasesMaleAntimetabolites AntineoplasticAdolescentBone Neoplasms030204 cardiovascular system & hematologyPharmacology03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Drug InteractionsRenal InsufficiencyPiperacillinOsteosarcomabusiness.industryNeurotoxicitymedicine.diseaseHigh dose methotrexateAnti-Bacterial AgentsMethotrexateOncology030220 oncology & carcinogenesisPiperacillin/tazobactamOsteosarcomaMethotrexateNeurotoxicity SyndromesbusinessPharmacokinetic interactionmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

COX-2 expression in chondrosarcoma: A role for celecoxib treatment?

2010

Chondrosarcomas are resistant to conventional chemo- and radiotherapy. A subset of chondrosarcomas arises secondarily in the benign tumour syndromes enchondromatosis (EC) and multiple osteochondromas (MO), and prevention of tumour development would greatly improve prognosis. We therefore investigated the effect of selective COX-2 inhibition on chondrosarcoma growth. COX-2 expression was studied in central- and peripheral cartilaginous tumours. The effect of COX-2 inhibition was assessed in four high-grade chondrosarcoma cell lines using celecoxib and NS-398 treatment. COX-2 activity (prostaglandin E-2 (PGE(2)) ELISA) and cell viability were measured. The (prophylactic) effect of celecoxib o…

musculoskeletal diseasesMaleCancer ResearchPathologymedicine.medical_specialtyCell Survivalmedicine.medical_treatmentChondrosarcomaDrug Evaluation PreclinicalMice NudeAntineoplastic AgentsBone NeoplasmsMiceIn vivomedicineTumor Cells CulturedAnimalsHumansViability assaySulfonamidesCyclooxygenase 2 Inhibitorsbusiness.industryCartilagemedicine.diseaseXenograft Model Antitumor AssaysRadiation therapyDisease Models Animalmedicine.anatomical_structureOncologyBone tumours Chondrosarcoma COX-2 inhibition Therapy Xenograft familial adenomatous polyposis cell-line cyclooxygenase-2 inhibitor trial tumors establishment emphasis origin boneCell cultureCelecoxibCyclooxygenase 2CelecoxibPyrazolesChondrosarcomabusinessmedicine.drugProstaglandin E
researchProduct

Cells of extramammary Paget's disease express cytokeratins different from those of epidermal cells.

1985

The patterns of expression of cytokeratin polypeptides which are closely correlated to routes of differentiation of epithelial cells were studied in extramammary Paget's disease. Cytokeratins of uninvolved and involved epidermis were analyzed by two-dimensional gel electrophoresis of microdissected tissue preparations as well as by immunofluorescence microscopy using cytokeratin antibodies with different specificities. In uninvolved epidermis, cytokeratins Nos. 1, 5, 6, 10, 11, 14, and 16, characteristic of keratinocytes, were found. Epidermis infiltrated by Paget's cells contained the same components and, in addition, cytokeratins Nos. 7, 8, 18, and 19, the latter being characteristic of s…

musculoskeletal diseasesMalePathologymedicine.medical_specialtySkin NeoplasmsDuctal cellsCellular differentiationFluorescent Antibody TechniqueDermatologyHistogenesisBiologyExtramammary Paget's diseaseBiochemistryCytokeratinotorhinolaryngologic diseasesmedicineHumansMolecular BiologyAgedSkinEpidermis (botany)Staining and LabelingApocrineCell Biologymedicine.diseasemedicine.anatomical_structurePaget Disease ExtramammaryKeratinsKeratinocytePeptidesImmunoelectrophoresis Two-DimensionalThe Journal of investigative dermatology
researchProduct